- This event has passed.
The Orbital Lab
February 25 @ 10:00 am - 11:00 am UTC-7
From conception, living organisms are continuously under the influence of gravity. Gravity has always been a constant. But what if gravity was a variable? Over the past 20 years, humans have had a continuous presence in Low Earth Orbit (LEO) where we have used the International Space Station (ISS) to study the effects of microgravity, revealing it to be a unique environment for studying biological processes that yield important insights for biotech and pharmaceutical discovery and development. Axiom and its partners are building the next generation life science research and manufacturing facility in LEO with tools and hardware comparable to modern labs on Earth. Elevating these capabilities in space helps support and drive biomedical research endeavors that benefit humanity on Earth, including the development, testing and manufacturing of new drugs and therapies.
In this first-of-a-kind truly Larger Than Life Science webinar, meet the visionaries who are charting a path to a new kind of innovation platform in this panel discussion moderated by Greg Horowitt, Co-Founder & Managing Director at T2 Venture Capital. We invite you to explore how microgravity is shifting our thinking about biology and how space can be a new platform for drug discovery, production and innovation.
Greg Horowitt, Cofounder and Managing Director, T2 Venture Creation
Greg has spent 25+ years working in startups and venture capital. He is the co-author of the bestselling book, The Rainforest: The Secret to Building the Next Silicon Valley and has consulted on innovation with top organizations like the Aspen Institute, National Academies of Science, World Bank, and US Department of State. He worked under Warren Buffett as an executive at a Berkshire Hathaway operating company, is a Kauffman Fellow, and has been a founder, investor, and board member in many leading organizations.
Jana Stoudemire, Commercial Innovation Officer, Space Tango
As the Commercial Innovation Officer at Space Tango, Jana leads the development of commercial
market creation in Low Earth Orbit (LEO) for biomedical and technology research and
manufacturing applications. She transitioned from pharma to lead life science research in
microgravity initially as part of the team managing the International Space Station, U.S. National
Laboratory (ISS-NL), and then joined Space Tango to focus on building an emerging market on
orbit representing new sectors of the Space economy.
Catriona Jamieson MD PhD, Professor of Medicine at UC San Diego
Dr. Jamieson is a leading physician-scientist who discovered missplicing, RNA hyper-editing and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. This pioneering cancer stem cell research has transformed therapies, including JAK2 and sonic hedgehog-inhibitor trials for myeloproliferative neoplasm and leukemia stem cell targeting. Dr. Jamieson is extending her research into space as a co-investigator. With a three-year, nearly $5 million award from NASA, she will be studying the effects of microgravity on stem cell self-renewal.
Anjali Gupta PhD, Business Development Life Science Lead at Axiom Space
Anjali is leading the life science business development efforts for in-space research and manufacturing at Axiom Space, where she is responsible for new partnerships as well as current collaborations across the life science industry spectrum. Anjali has over fifteen years of experience in the pharmaceutical and biotech industries. At Axiom Space, Anjali hopes to turn science-fiction into science-reality through strategic partnerships that aim to leverage the unique microgravity environment of space for research, development, and manufacturing of innovative products, processes, and services benefiting humankind on Earth and explorations beyond.